Noticia de Contratación

  • Inicio
  • Noticias
  • Biosimilares
  • European Medicines Agency accepted first “China-Developed” biosimilar – Henlius HLX02 MAA for review
cluster-farma-asociacion-de-laboratorios-farmaceuticos-ecuatorianos-Medicamentos-biosimilares-conoce-un-poco-más-sobre-ellos-C.jpg
27/06/2019 08:34:51
Fuente original

European Medicines Agency accepted first “China-Developed” biosimilar – Henlius HLX02 MAA for review

Henlius, a biotech company in China developing both biosimilar and innovative biologics, announced that the European Medicines Agency (EMA) has officially accepted to review the Marketing Authorization Application (MAA) of its trastuzumab biosimilar HLX02.



Leer el artículo original completo

Asesoría en Contratación Pública Sanitaria

C/ Orense, 34
28020 Madrid
acobur@acobur.es
91 448 39 07
Lunes a Viernes de 8:30h a 18:00h

Servicios
 

2016 © Todos los derechos reservados. Aviso legal | Condiciones del servicio | Uso de Cookies | Redes Sociales